How would you approach a patient with Stage III EGFR+ NSCLC who develops oligometastatic disease while on consolidation durvalumab?
Given the potential high risk of developing pneumonitis with TKI post checkpoint inhibitor, do you avoid TKIs and try a different regimen (ex carbo/paclitaxel/bev +/- atezo)?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · UCSD Moores Cancer Center
Answered on
This is a difficult situation, I have typically tried local therapies like SBRT initially and then switching to osimertinib with close followup and return precautions
Join for free or sign in to see the full answer